Sponsor

Peter MacCallum Cancer Centre, Australia

Clinical research sponsor

How to interpret these research links

Connected source records

The exact organization name Peter MacCallum Cancer Centre, Australia appears in 38 distinct published trial records. The links retain registry-reported sponsor and collaborator roles; differently spelled legal entities are not automatically merged. Recruiting status describes the current published registry snapshot, not an independently verified availability guarantee.

Data basis: current published ClinicalTrials.gov records and, where present, RxNorm, MONDO and FDA-label identifiers. See the evidence interpretation and counting methodology.

Published trials38
Recruiting shown7
Roles2
SourceClinicalTrials.gov
Advertisement

Clinical trials

38 shown
Lu-PSMA for Oligometastatic Prostate Cancer Treated With STereotactic Ablative RadiotherapyNCT05560659 · lead sponsor · 2023-12-14
RECRUITING
EValuation of radIOLigand Treatment in mEn With Metastatic Castration-resistant Prostate Cancer With [161Tb]Tb-PSMA-I&TNCT05521412 · lead sponsor · 2022-09-29
RECRUITING
Stereotactic Ablative Body Radiotherapy (SABR) With Maintenance of Systemic Therapy Versus Physicians' Choice of Systemic Therapy for Oligoprogressive ER-positive, Her-2 Negative Breast Cancer IINCT06882499 · lead sponsor · 2026-11-01
NOT_YET_RECRUITING
Evaluating Ovarian Toxicity Outcomes Following Immunotherapy in Patients With Triple-Negative Breast Cancer (TNBC)NCT07527819 · lead sponsor · 2026-04-08
NOT_YET_RECRUITING
Phase Ib Trial of 177Lu-PSMA-I&T Therapy in Combination With Olaparib and Pembrolizumab in Patients With Metastatic Castration Resistant Prostate CancerNCT07090369 · lead sponsor · 2025-11-01
NOT_YET_RECRUITING
Pidnarulex and Talazoparib in Patients With Metastatic Castration Resistant Prostate CancerNCT05425862 · lead sponsor · 2022-10-21
SUSPENDED
Combination of Radium-223 and Lutetium-177 PSMA-I&T in Men with Metastatic Castration-Resistant Prostate CancerNCT05383079 · lead sponsor · 2022-09-13
ACTIVE_NOT_RECRUITING
Cabazitaxel in Combination With 177Lu-PSMA-617 in Metastatic Castration-resistant Prostate CancerNCT05340374 · lead sponsor · 2022-07-14
ACTIVE_NOT_RECRUITING
PSMA PET Additive Value for Prostate Cancer Diagnosis in Men With Negative/Equivocal MRINCT05154162 · lead sponsor · 2022-03-02
ACTIVE_NOT_RECRUITING
PRIME_LUNG: Primary Radiotherapy In MEtastatic Lung Cancer - A Pilot StudyNCT05222087 · lead sponsor · 2022-01-03
UNKNOWN
ProsTIC Registry of Men Treated With PSMA TheranosticsNCT04769817 · lead sponsor · 2021-05-19
ACTIVE_NOT_RECRUITING
Evaluating the Efficacy and Safety of Bevacizumab, Carboplatin, Gemcitabine and Atezolizumab in Breast CancerNCT04739670 · lead sponsor · 2021-03-01
UNKNOWN
COVID-19 Prevention and Treatment in Cancer; a Sequential Multiple Assignment Randomised Trial;NCT04534725 · lead sponsor · 2020-12-17
COMPLETED
Dosimetry, Safety and Potential Benefit of 177Lu-PSMA-617 Prior to ProstatectomyNCT04430192 · lead sponsor · 2020-08-06
ACTIVE_NOT_RECRUITING
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer: the VAPOR-C TrialNCT04316013 · lead sponsor · 2020-07-31
TERMINATED
In Men With Metastatic Prostate Cancer, What is the Safety and Benefit of Lutetium-177 PSMA Radionuclide Treatment in Addition to ChemotherapyNCT04343885 · lead sponsor · 2020-04-21
ACTIVE_NOT_RECRUITING
Palbociclib, Letrozole & Venetoclax in ER and BCL-2 Positive Breast CancerNCT03900884 · lead sponsor · 2019-09-25
ACTIVE_NOT_RECRUITING
PRINCE (PSMA-lutetium Radionuclide Therapy and ImmuNotherapy in Prostate CancEr)NCT03658447 · lead sponsor · 2019-07-12
COMPLETED
177Lu-PSMA-617 Therapy and Olaparib in Patients With Metastatic Castration Resistant Prostate CancerNCT03874884 · lead sponsor · 2019-07-09
ACTIVE_NOT_RECRUITING
Stereotactic Radiation and Immunotherapy in Patients With Advanced Triple Negative Breast CancerNCT03464942 · lead sponsor · 2018-08-01
COMPLETED
High Intensity Functional Image Guided Vmat Lung EvasionNCT03569072 · lead sponsor · 2018-07-01
COMPLETED
Sequencing of Stereotactic Ablative Body Radiotherapy in Combination With PD-1 Blockade Using Pembrolizumab in Metastatic Non-Small Cell Lung CarcinomaNCT03307759 · lead sponsor · 2017-12-07
TERMINATED
Volatile Anaesthesia and Perioperative Outcomes Related to Cancer Feasibility StudyNCT04074460 · lead sponsor · 2017-08-27
COMPLETED
Phosphatidylinositol 3-kinase (PI3K) Alpha iNhibition In Advanced Breast CancerNCT02506556 · lead sponsor · 2015-09-07
COMPLETED
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475NCT02303366 · lead sponsor · 2015-09-01
COMPLETED
Androgen Deprivation Therapy in Treating Patients With Prostate CancerNCT00110162 · lead sponsor · 2004-10-01
UNKNOWN
Ventilation Imaging to Improve the Quality of Life for Patients With Lung Cancer Treated With Radiation TherapyNCT06127654 · collaborator · 2026-01-01
RECRUITING
Implementing Surgery School Prehabilitation Using TelehealthNCT06631872 · collaborator · 2025-01-22
RECRUITING
National Robotics-Assisted Radical Prostatectomy DatabaseNCT06279260 · collaborator · 2024-07-01
RECRUITING
Partial Breast Re-irradiation Using Ultra Hypofractionation (PRESERVE)NCT05592938 · collaborator · 2023-06-27
RECRUITING
LEARN: Learning Environment for Artificial Intelligence in Radiotherapy New TechnologyNCT05184790 · collaborator · 2023-02-28
RECRUITING
Australian Retrospective Analysis of EGFRm Advanced & Metastatic NSCLC Patients Treated With 1L or 2L Osimertinib.NCT07213076 · collaborator · 2025-07-04
COMPLETED
Biomarker-driven Intermittent Docetaxel in Metastatic Castration-resistant Prostate CancerNCT04918810 · collaborator · 2022-07-29
TERMINATED
Darolutamide + Consolidation Radiotherapy in Advanced Prostate Cancer Detected by PSMANCT04319783 · collaborator · 2021-06-02
ACTIVE_NOT_RECRUITING
Age-related Clonal Haematopoiesis in an HIV Evaluation Cohort (ARCHIVE)NCT04641013 · collaborator · 2017-12-05
ACTIVE_NOT_RECRUITING
A Feasibility Trial Using Lithium As A Neuroprotective Agent In Patients Undergoing Prophylactic Cranial Irradiation For Small Cell Lung CancerNCT01486459 · collaborator · 2012-11-01
TERMINATED
Accelerated Partial Breast Irradiation for Early Breast CancerNCT00418210 · collaborator · 2007-08-01
COMPLETED
Lung Tumour Volume DatabaseNCT00351598 · collaborator · 1999-09-01
COMPLETED

Drugs studied in this sponsor's trials

18 mapped RxNorm concepts

These drug records are connected through ClinicalTrials.gov studies listing Peter MacCallum Cancer Centre, Australia as a sponsor, collaborator or responsible party. Each count is the number of distinct trials containing the mapped drug intervention. This does not establish that the organization manufactures, owns, sells or developed the drug.

Most studied mapped drug conceptsDistinct linked trials per RxNorm concept; one trial may study several drugs.
lutetium Lu 177 vipivotide tetraxetan3
pembrolizumab3
atezolizumab2
propofol2
bevacizumab1
cabazitaxel1
carboplatin1
darolutamide1
lutetium Lu 177 vipivotide tetraxetan RxCUI 2597053 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials pembrolizumab RxCUI 1547545 · Lead sponsor in 3 linked trial(s) · 0 currently recruiting 3 trials atezolizumab RxCUI 1792776 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials propofol RxCUI 8782 · Lead sponsor in 2 linked trial(s) · 0 currently recruiting 2 trials bevacizumab RxCUI 253337 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial cabazitaxel RxCUI 996051 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial carboplatin RxCUI 40048 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial darolutamide RxCUI 2180325 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial docetaxel RxCUI 72962 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial gemcitabine RxCUI 12574 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial letrozole RxCUI 72965 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial lithium RxCUI 6448 · Lead sponsor in 0 linked trial(s) · 0 currently recruiting 1 trial olaparib RxCUI 1597582 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial palbociclib RxCUI 1601374 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial selinexor RxCUI 2178390 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial sevoflurane RxCUI 36453 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial talazoparib RxCUI 2099704 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial venetoclax RxCUI 1747556 · Lead sponsor in 1 linked trial(s) · 0 currently recruiting 1 trial

Sponsor roles

lead sponsor26
collaborator12
Advertisement

Registry-derived research relationships: ClinicalTrials.gov. Raw condition and intervention labels remain distinct from canonical MONDO/RxNorm entities unless separately normalized.